These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20510717)

  • 41. Thyrotropin in the development and management of differentiated thyroid cancer.
    McLeod DS
    Endocrinol Metab Clin North Am; 2014 Jun; 43(2):367-83. PubMed ID: 24891167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiated thyroid carcinoma: defining new paradigms for postoperative management.
    Durante C; Costante G; Filetti S
    Endocr Relat Cancer; 2013 Aug; 20(4):R141-54. PubMed ID: 23572163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Thyroid cancer: metabolic treatment and follow-up using thyroglobulin levels and I-131 gammagraphy].
    Lampreave JL; Trampal C; Domínguez P; Bittini A
    Rev Clin Esp; 1998 May; 198(5):307-15. PubMed ID: 9658914
    [No Abstract]   [Full Text] [Related]  

  • 44. Radioiodine-resistant differentiated thyroid cancer: hope for the future.
    Hodak SP; Carty SE
    Oncology (Williston Park); 2009 Aug; 23(9):775-6. PubMed ID: 19777763
    [No Abstract]   [Full Text] [Related]  

  • 45. Simultaneous medullary-papillary thyroid carcinoma.
    Al-Mashat FM
    Ann Saudi Med; 2004; 24(3):213-5. PubMed ID: 15307464
    [No Abstract]   [Full Text] [Related]  

  • 46. Contemporary post surgical management of differentiated thyroid carcinoma.
    Tala H; Tuttle RM
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):419-29. PubMed ID: 20605708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thyroid cancer: what to do after fine needle aspiration.
    Rometo DA; Baranski TJ
    Mo Med; 2011; 108(2):93-8. PubMed ID: 21568229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synchronous occurrence of macroscopic papillary and medullary thyroid carcinomas.
    López JI; Ruiz A; Ugarte E; Paja M; Ereño C; Gaafar A
    Hematol Oncol Stem Cell Ther; 2008; 1(3):193-6. PubMed ID: 20063552
    [No Abstract]   [Full Text] [Related]  

  • 49. A thyroid nodule overtreated twice.
    Yu R
    Endocrinol Diabetes Nutr; 2017; 64(7):396-397. PubMed ID: 28968220
    [No Abstract]   [Full Text] [Related]  

  • 50. Impact of pregnancy on outcome and prognosis of survivors of papillary thyroid cancer.
    Hirsch D; Levy S; Tsvetov G; Weinstein R; Lifshitz A; Singer J; Shraga-Slutzky I; Grozinski-Glasberg S; Shimon I; Benbassat C
    Thyroid; 2010 Oct; 20(10):1179-85. PubMed ID: 20860423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of at least five years after recombinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine.
    Rosario PW; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Mar; 22(3):332-3. PubMed ID: 22233130
    [No Abstract]   [Full Text] [Related]  

  • 52. [Rare adverse effect of discontinuation of levothyroxine treatment for 131I ablation of thyroid remnant in a patient with differentiated thyroid cancer].
    Luque-Ramírez M; Gómez Ramírez J; Azcárate Villalón A; Martín Pérez E; Larrañaga Barrera E
    Endocrinol Nutr; 2013; 60(7):412-4. PubMed ID: 23271037
    [No Abstract]   [Full Text] [Related]  

  • 53. The role of external beam radiation and targeted therapy in thyroid cancer.
    Brierley J; Sherman E
    Semin Radiat Oncol; 2012 Jul; 22(3):254-62. PubMed ID: 22687950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?].
    Chebotareva ED; Shishkina VV
    Lik Sprava; 1997; (1):118-22. PubMed ID: 9221132
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of thyroid cancer.
    Blahd WH
    Compr Ther; 1993; 19(5):197-202. PubMed ID: 8275665
    [No Abstract]   [Full Text] [Related]  

  • 56. Controversies in the follow-up and management of well-differentiated thyroid cancer.
    Ringel MD; Ladenson PW
    Endocr Relat Cancer; 2004 Mar; 11(1):97-116. PubMed ID: 15027888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Postoperative treatment of differentiated thyroid carcinoma with radioiodine-131].
    Lin YS
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):62-68. PubMed ID: 30704175
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current concepts in the follow-up of patients with differentiated thyroid cancer.
    Benbassat CA; Mechlis-Frish S; Guttmann H; Glaser B; Krausz Y
    Isr Med Assoc J; 2007 Jul; 9(7):540-5. PubMed ID: 17710787
    [No Abstract]   [Full Text] [Related]  

  • 59. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.
    Verburg FA; Dietlein M; Lassmann M; Luster M; Reiners C
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):343-6. PubMed ID: 19050874
    [No Abstract]   [Full Text] [Related]  

  • 60. Visual vignette.
    Satya R; Muthukrishnan A; Rosenthal RS; Ojha BC
    Endocr Pract; 2004; 10(4):384. PubMed ID: 15760785
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.